ArticleCureus2025
Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with type 2 diabetes mellitus (T2DM) have a high-risk condition of developing cardiovascular disease, and therefore, therapeutic strategies should consider cardiovascular risk reduction. Previously, we demonstrated that circulating glucagon-like peptide-1 (GLP-1) levels are significantly lower in Japanese patients with coronary artery disease (CAD) compared with non-CAD subjects. Once-weekly semaglutide, a GLP-1 receptor agonist, has demonstrated clinical cardiometabolic benefits; however, its effect on vascular endothelial function in Japanese patients with T2DM remains unclear.
methodsThis retrospective observational study included patients with T2DM who were hospitalized at Jinnouchi Hospital and initiated once-weekly subcutaneous semaglutide therapy since 2021. Vascular endothelial function was assessed using reactive hyperemia peripheral arterial tonometry, expressed as the reactive hyperemia index (RHI), before and after semaglutide treatment. Clinical parameters including body weight (BW), glycated hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol (LDL-cho), and high-sensitivity C-reactive protein (hsCRP) were also evaluated.
resultsA total of 24 patients (mean age: 55 years; n=20 (83.3%) male) were included. RHI significantly increased following semaglutide therapy (baseline: 1.62±0.19 versus follow-up: 2.04±0.60; p<0.01). BW, HbA1c, and LDL-cho also showed significant reductions (all p<0.01). HsCRP tended to decrease, though not significantly. None of the changes in BW, HbA1c, LDL-cho, or hsCRP correlated with the changes in RHI.
conclusionOnce-weekly semaglutide treatment significantly provided potential improvement in vascular endothelial function in Japanese patients with T2DM, supporting the cardiovascular protective role of semaglutide therapy in the clinical management of T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.